VectorXcellerator Programme
OXB is pleased to announce Cure Lowe Foundation as one of the selected programmes . The programme was selected following a comprehensive review of applications across lentiviral vector and AAV programmes, for its scientific rationale, platform alignment and development readiness.
Application info
2026 application cycle complete
Application cycle complete
Applications for VectorXcellerator cycle are now closed. Following review by OXB teams, selected programmes have now been identified and notified.
Programmes selected through VectorXcellerator
Cure Lowe Foundation
OXB is pleased to announce Cure Lowe Foundation as one of the selected programmes.
The programme was selected following a comprehensive review of applications across lentiviral vector and AAV programmes, for its scientific rationale, platform alignment and development readiness.
Why VectorXcellerator?
Early development decisions can have long-term implications for cell and gene therapy programmes, particularly when it comes to vector design, process development, manufacturability, and scalability.
VectorXcellerator has been created to support organisations developing promising early-stage programmes by generating feasibility-level data and technical confidence to guide next development steps, with no obligation for future commercial engagement.
Looking ahead
VectorXcellerator was created to support earlier collaboration between OXB and emerging innovators in advanced therapies. Follow OXB on LinkedIn for updates on selected programmes, technical insights and future VectorXcellerator developments.
Receive future VectorXcellerator updates and collaboration opportunities directly to your inbox
Frequently asked questions
There is no cost to apply. Selected feasibility studies are fully funded by OXB.
Selected companies will receive a feasibility-level technical study aligned to pre-agreed objectives. The precise scope and deliverables will be confirmed prior to project initiation.
Applicants are reviewed by a cross-functional OXB panel and assessed holistically across several factors, including scientific and technical readiness, alignment with OXB’s platform capabilities, team experience, and robustness of development plan.
No. Participation in VectorXcellerator does not imply any obligation for future commercial engagement by either party.
A successful feasibility study may inform future discussions; however, any subsequent collaboration would be subject to separate evaluation and agreement and is not guaranteed as part of the VectorXcellerator initiative.
All applicants will be notified of the outcome. Due to the nature of the initiative, OXB may not be able to provide detailed individual feedback.
OXB reserves the right to modify, suspend, or withdraw the VectorXcellerator initiative prior to commencement of any feasibility study.
Disclaimer
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation.
These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US.
Learn more at www.oxb.com and follow us on LinkedIn and YouTube.